SPS
BDTX icon

Susquehanna Portfolio Strategies’s Black Diamond Therapeutics BDTX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$370K Buy
173,647
+14,663
+9% +$34.9K 0.01% 810
2025
Q4 		$386K Sell
158,984
-52,098
-25% -$185K 0.01% 833
2025
Q3 		$800K Buy
211,082
+153,939
+269% +$450K 0.01% 728
2025
Q2 		$142K Buy
+57,143
New +$110K ﹤0.01% 809

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna Portfolio Strategies's BDTX Position: Q1 2026 in Review

Susquehanna Portfolio Strategies increased its Black Diamond Therapeutics (BDTX) stake by 9.2% in Q1 2026, buying an estimated $34.9K and bringing the position to 173,647 shares worth $370K. The position accounts for 0.01% of the portfolio, ranked #810.

Susquehanna Portfolio Strategies first reported a position in BDTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $800K in Q3 2025. 104 funds tracked by Wall St. Rank hold BDTX as of Q1 2026.

  • Susquehanna Portfolio Strategies held 173,647 shares of Black Diamond Therapeutics worth $370K as of Q1 2026.
  • Susquehanna Portfolio Strategies bought 14,663 Black Diamond Therapeutics shares in Q1 2026, an estimated $34.9K.
  • Black Diamond Therapeutics made up 0.01% of Susquehanna Portfolio Strategies's portfolio in Q1 2026, its #810 holding.
  • Susquehanna Portfolio Strategies first reported a position in Black Diamond Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Susquehanna Portfolio Strategies's Black Diamond Therapeutics position peaked at $800K in Q3 2025.
  • 104 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q1 2026, filed 15 May 2026.